![](https://www.worldpharmatoday.com/images/nBanners/Docuvera-728x90.jpeg")
Clinical Trials
Bharat Biotech underplays adverse event in Covaxin Phase 1 trial as start date for Phase 3 nears
Bharat Biotech, during its phase 1 trials, experienced an adverse event in a volunteer that it did not promptly admit to the public. As...
Clinical Trials
Astrazeneca Says AZD1222 vaccine met primary efficacy endpoint in preventing COVID-19
Positive high-level results from an interim analysis of clinical trials of AZD1222 in the UK and Brazil showed the vaccine was highly effective in...
Clinical Trials
EUA Begins Rolling Review of Modernas mRNA Vaccine Candidate Against COVID-19
Moderna, Inc.,a biotechnology company pioneering messenger RNA therapeutics and vaccines to create a new generation of transformative medicines for patients, announced that the EMA...
Clinical Trials
Mallinckrodt Initiates Retrospective Study of the Use of Inhaled Nitric Oxide in COVID-19 Patients
Mallinckrodt plc, a global biopharmaceutical company, announced initiation of a retrospective chart review study, titled "Nitric Oxide Treatment In COVID-19 Evaluation (NOTICE)" to collect...
Clinical Trials
Cancer Treatment Can Be Cloned For COVID-19
As per the recent international study by the scientists from Italy & Australia, Beta-blockers have it in them to be a potential treatment for...
Clinical Trials
Pfizer and BioNTech Announce Vaccine Candidate Against COVID-19 Achieved Success in First Interim Analysis from Phase 3 Study
Pfizer Inc. and BioNTech SE announced their mRNA-based vaccine candidate, BNT162b2, against SARS-CoV-2 has demonstrated evidence of efficacy against COVID-19 in participants without prior...
Clinical Trials
Pfizer Announces Positive Phase 3 Study Results for XELJANZ in Ankylosing Spondylitis
Pfizer Inc. announced positive results from a Phase 3 investigational study evaluating the safety and efficacy of tofacitinib in adults with active ankylosing spondylitis...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from up to 5 devices at once
Must read